Dyax buys rights to angiogenesis technology:
This article was originally published in Clinica
Executive Summary
Biopharmaceutical company Dyax has bought exclusive rights to develop diagnostic products and antibody drugs for an undisclosed angiogenesis target from Licentia. Helsinki, Finland-based Licentia focuses on licensing and commercialising scientific research results. Its shareholders include the University of Helsinki and the Helsinki University of Technology. Dyax has also formed a research collaboration with Dr Kari Alitalo from the University of Helsinki.